Insider · CIK 0001703031
Bain Capital Life Sciences Investors, LLC
Files at SLDB (Solid Biosciences Inc.), OLMA (Olema Pharmaceuticals, Inc.), NAMS (NewAmsterdam Pharma Co N.V.). First filing Jan 13, 2025, latest Feb 21, 2025.
Where the trades landed
Last year at the 2 companies this insider has traded most, with each buy and sell on the bar it happened.
SLDB: Solid Biosciences Inc.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value. Click a marked bar to open the signal.Charts by TradingView Lightweight Charts™
OLMA: Olema Pharmaceuticals, Inc.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value. Click a marked bar to open the signal.Charts by TradingView Lightweight Charts™
Signals
This insider’s open-market buys and sells, scored.
| Score | Company | Value | Holdings | Price context | Filed |
|---|---|---|---|---|---|
| 53Moderate | Solid Biosciences Inc. | $4.0M 1,000,000 shares | +25% | - | |
| 32Weak | OLMAbuy Olema Pharmaceuticals, Inc. | $1.7M 300,000 shares | +4% | - |
Transactions
Every row this insider has filed, newest first.
| Date | Company | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Feb 19, 2025 | SLDB Solid Biosciences Inc. | POpen-market purchase Common Stockindirect: See footnotes | +1,000,000 | $4.03 | $4.0M | 5,034,582 | Feb 21, 2025 |
| Feb 19, 2025 | SLDB Solid Biosciences Inc. | POpen-market purchase Pre-Funded Warrant (right to buy)derivativeindirect: See footnotes | +6,444,170 | $4.03 | $26M | 6,444,170 | Feb 21, 2025 |
| Jan 8, 2025 | OLMA Olema Pharmaceuticals, Inc. | POpen-market purchase Common Stockindirect: See footnotes | +300,000 | $5.76 | $1.7M | 7,800,000 | Jan 13, 2025 |
| Jan 10, 2025 | OLMA Olema Pharmaceuticals, Inc. | JOther Common Stockindirect: See footnotes | -3,500,000 | - | - | 4,300,000 | Jan 13, 2025 |
| Jan 10, 2025 | OLMA Olema Pharmaceuticals, Inc. | JOther Pre-Funded Warrant (right to buy)derivativeindirect: See footnotes | +3,500,000 | - | - | 3,500,000 | Jan 13, 2025 |
| Dec 13, 2024 | NAMS NewAmsterdam Pharma Co N.V. | POpen-market purchase Pre-Funded Warrant (right to buy)derivativeindirect: See footnotes | +1,632,653 | $24.50 | $40M | 1,632,653 | Dec 17, 2024 |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.